On January 19, 2023, the U.S. Food and Drug Administration granted accelerated approval to Tucatinib plus Trastuzumab for adult patients with RAS wild-type metastatic colon cancer with HER2-positive status as detected at
Janakpurdham, Nepal, April 27, 2022 – The Binaytara Foundation hosted its Fourth International Cancer Congress on April 16, bringing together scientists and healthcare workers to share the latest findings in cancer care.
MoreOncologists Interested in Improving Access to Cancer Care Encouraged to Apply Are you an oncologist who is passionate about educating fellow providers? We invite you to apply to join the Binaytara Foundation
MoreFaculty highlight, Dr. Joseph Rosales!
MoreASH Review Portland, Highlights from SABCS, and Thoracic Oncology San Diego The Binaytara Foundation is facilitating three conferences with varying focuses at the beginning of the year. These meetings include BTF’s ASH
MoreMeet Chris Nevala-Plagemann, MD, Katie Kerrigan, DO, and Theresa Werner, MD! In this week’s faculty highlight, we present Drs. Chris Nevala-Plagemann, Katie Kerrigan, and Theresa Werner. These three doctors joined us as
MoreLocal Oncologist Involved with the Binaytara Foundation Since 2019 Meet Dr. Fengting Yan, one of our wonderful Education Committee members! Dr. Yan is an oncologist who specializes in women’s cancer practicing at
MoreThe addition of Dr. Anand Nayak and Mr. Santosh Ray’s Expertise Has Led to an Enhanced Histopathology Laboratory Dr. Anand Kumar Nayak recently joined the BTFCC as a consultant pathologist, and the
MoreThe conference will be held at the Grand Hyatt in Seattle on April 28-30, 2023 We invite you to attend the 2023 Summit on Cancer Health Disparities (SCHD23) in Seattle, WA! This
MoreWatch the video faculty highlight from our Women's Cancer Conference!
MoreRead about the Binaytara Foundation October Conferences!
More